The observation that NaPi-IIb ablation in uremic mice causes a sustained decrease, although not always complete normalisation, of serum phosphate levels [50, 57] was used to support the idea that NaPi-IIb is a suitable treatment target for preventing or reducing hyperphosphatemia in CKD patients. Here, SLC34A2 is linked to hyperphosphatemia.